Unknown

Dataset Information

0

Failure of ceftolozane-tazobactam salvage therapy in complicated pneumonia with lung abscess.

ABSTRACT: Treatment of Pseudomonas aeruginosa remains challenging, despite the availability ceftolozane-tazobactam. We report a treatment failure with ceftolozane-tazobactam salvage therapy for pneumonia complicated by lung abscess. Drug resistance, dose selection, and source control are possible contributing factors. Ceftolozane-tazobactam susceptibility testing should precede therapy and consideration should be given to dosing selection.

SUBMITTER: Lewis PO 

PROVIDER: S-EPMC6028400 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Failure of ceftolozane-tazobactam salvage therapy in complicated pneumonia with lung abscess.

Lewis Paul O PO   Cluck David B DB   Tharp Jennifer L JL   Krolikowski Matthew A MA   Patel Paras D PD  

Clinical case reports 20180528 7

Treatment of <i>Pseudomonas aeruginosa</i> remains challenging, despite the availability ceftolozane-tazobactam. We report a treatment failure with ceftolozane-tazobactam salvage therapy for pneumonia complicated by lung abscess. Drug resistance, dose selection, and source control are possible contributing factors. Ceftolozane-tazobactam susceptibility testing should precede therapy and consideration should be given to dosing selection. ...[more]

Similar Datasets

Unknown Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections.
| S-EPMC5328537 | biostudies-literature
Unknown Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infections.
| S-EPMC4878668 | biostudies-literature
Unknown Ceftolozane/Tazobactam: a new option in the treatment of complicated gram-negative infections.
| S-EPMC4264669 | biostudies-other
Unknown Ceftolozane-Tazobactam Combination Therapy Compared to Ceftolozane-Tazobactam Monotherapy for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis.
| S-EPMC7830767 | biostudies-literature
Unknown Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections.
| S-EPMC4461093 | biostudies-literature
Unknown In Vitro Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for Pseudomonas aeruginosa.
| S-EPMC5700331 | biostudies-literature
Unknown Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
| S-EPMC5414364 | biostudies-literature
Unknown Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections.
| S-EPMC6535558 | biostudies-literature
Unknown Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia.
| S-EPMC7225904 | biostudies-literature
Unknown Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.
| S-EPMC5049594 | biostudies-literature